Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 4/2015

01.04.2015 | Review Article

Cancer patient decision making related to clinical trial participation: an integrative review with implications for patients’ relational autonomy

verfasst von: Jennifer A. H. Bell, Lynda G. Balneaves

Erschienen in: Supportive Care in Cancer | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Oncology clinical trials are necessary for the improvement of patient care as they have the ability to confirm the efficacy and safety of novel cancer treatments and in so doing, contribute to a solid evidence base on which practitioners and patients can make informed treatment decisions. However, only 3–5 % of adult cancer patients enroll in clinical trials. Lack of participation compromises the success of clinical trials and squanders an opportunity for improving patient outcomes. This literature review summarizes the factors and contexts that influence cancer patient decision making related to clinical trial participation.

Methods

An integrative review was undertaken within PubMed, CINAHL, and EMBASE databases for articles written between 1995 and 2012 and archived under relevant keywords. Articles selected were data-based, written in English, and limited to adult cancer patients.

Results

In the 51 articles reviewed, three main types of factors were identified that influence cancer patients’ decision making about participation in clinical trials: personal, social, and system factors. Subthemes included patients’ trust in their physician and the research process, undue influence within the patient-physician relationship, and systemic social inequalities. How these factors interact and influence patients’ decision-making process and relational autonomy, however, is insufficiently understood.

Conclusions

Future research is needed to further elucidate the sociopolitical barriers and facilitators of clinical trial participation and to enhance ethical practice within clinical trial enrolment. This research will inform targeted education and support interventions to foster patients’ relational autonomy in the decision-making process and potentially improve clinical trial participation rates.
Anhänge
Nur mit Berechtigung zugänglich
Fußnoten
1
It is not clear in many of these studies whether physicians informing patients about CTs were treating physicians or physician-investigators. This difference may have important implications for patients’ relational autonomy. For example, the dual role of physician-investigators may impact the trust patients have in these physicians and the way in which information was provided, since physician-investigators could have secondary interests that conflict with the patient’s best interest.
 
2
Clinical equipoise means there is genuine uncertainty in the expert medical community about whether a treatment will be beneficial [82].
 
Literatur
1.
Wasan AD, Taubenberger SP, Robinson WM (2009) Reasons for participation in pain research: can they indicate a lack of informed consent? Pain Med 10:111–119CrossRefPubMed
2.
Lee SJ, Lenert L, Weisman S, Kavanaugh A (2005) Factors affecting rheumatoid arthritis patients’ decisions to participate in clinical trials. J Rheumatol 32:2317–2325PubMed
3.
Unson CG, Dunbar N, Curry L, Kenyon L, Prestwood K (2001) The effects of knowledge, attitudes, and significant others on decisions to enroll in a clinical trial on osteoporosis: implications for recruitment of older African-American women. J Natl Med Assoc 93:392–401, discussion 402–4PubMedCentralPubMed
4.
Burgess LJ, Sulzer NU, Hoosain F, Leverton N, Bliganut S, Emanuel S (2009) Patients’ motivations for participating in cardiovascular clinical trials: a local perspective. Cardiovasc J Afr 20:220–223PubMedCentralPubMed
5.
Glover M, Kira A, Johnston V, Walker N, Thomas D, Change A, Bullen C, Segan CJ, Brown N (2014) A systematic review of barriers and facilitators to participation in randomized controlled trials by indigenous people from New Zealand, Australia, Canada and the United States. Glob Health Promot [Epub ahead of print]
6.
Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau D, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS (2001) Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. JCO 19:1728–1733
7.
Stark N, Paskett E, Bell R, Cooper MR, Walker E, Wilson A, Tatum C (2002) Increasing participation of minorities in cancer clinical trials: summary of the “Moving Beyond the Barriers” Conference in North Carolina. J Natl Med Assoc 94:31–39
8.
Tejada HA, Green SB, Trimble EL et al (1996) Representation of African-Americans, Hispanics, and whites in National Cancer Institute treatment trials. J Natl Cancer Inst 88:812–816CrossRef
9.
Sateren WB, Trimble EL, Abrams J, Brawley O, Breen N, Ford L, McCabe M, Kaplan R, Smith M, Ungerleider R, Christian MC (2002) How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. JCO 20:2109–2117CrossRef
10.
11.
Canadian Cancer Research Alliance (2011) Report on the state of cancer clinical trials in Canada. CCRA, Toronto
12.
Cheng SK, Dietrich MS, Dilts DM (2011) Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials. Clin Cancer Res 17:1947–1955CrossRefPubMedCentralPubMed
13.
Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, Wilson K, Ellis P, Wright JR (2006) Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol 7:141–148CrossRefPubMed
14.
Biedrzycki BA (2010) Decision making for cancer clinical trial participation: a systematic review. Oncol Nurs Forum 37:E387–E399CrossRefPubMed
15.
Cox K, McGarry J (2003) Why patients don’t take part in cancer clinical trials: an overview of the literature. Eur J Cancer Care 12:114–122CrossRef
16.
Townsley CA, Selby R, Siu LL (2005) Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 23:3112–3124CrossRefPubMed
17.
Schmotzer GL (2012) Barriers and facilitators to participation of minorities in clinical trials. Ethn Dis 22:226–230PubMed
18.
Dixon-Woods M, Bonas S, Booth A, Jones DR, Miller T, Sutton AJ, Shaw RL, Smith JA, Young B (2006) How can systematic reviews incorporate qualitative research? A critical perspective. Qual Res 6:27–44CrossRef
19.
Beauchamp TL, Childress JF (2012) Principles of biomedical ethics. Oxford University Press, New York
20.
Sherwin S (1998) A relational approach to autonomy in health care. In: Sherwin S, the Feminist Health Care Ethics Research Network (eds) The politics of women’s health: exploring agency and autonomy. Temple University Press, Philadelphia, pp 19–47
21.
Paskett ED, Cooper MR, Stark N, Ricketts TC, Tropman S, Hatzell T, Aldrich T, Atkins J (2002) Clinical trial enrollment of rural patients with cancer. Cancer Pract 10:28–35CrossRefPubMed
22.
Sharkey K, Savulescu J, Aranda S, Schofield P (2010) Clinician gate-keeping in clinical research is not ethically defensible: an analysis. J Med Ethics 36:363–366CrossRefPubMed
23.
Whittemore R, Knafl K (2005) The integrative review: updated methodology. J Adv Nurs 52:546–553CrossRefPubMed
24.
Klabunde C, Kaluzny A, Ford L (1995) Community Clinical Oncology Program participation in the breast cancer prevention trial: factors affecting accrual. Cancer Epidemiol Biomarkers Prev 4:783–789PubMed
25.
Klabunde CN, Kaluzny AD (1995) Accrual to the breast cancer prevention trial by participating Community Clinical Oncology Programs: a panel data analysis. Breast Cancer Res Treat 35:43–50CrossRefPubMed
26.
Advani AS, Atkeson B, Brown CL, Peterson BL, Fish L, Johnson JL, Gockerman JP, Gautier M (2003) Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study. Cancer 97:1499–1506CrossRefPubMed
27.
Ellis PM, Butow PN, Tattersall MHN, Dunn SM, Houssami N (2001) Randomized clinical trials in oncology: understanding and attitudes predict willingness to participate. JCO 19:3554–3561
28.
Go RS, Frisby KA, Lee JA (2006) Clinical trial accrual among new cancer patients at a community-based cancer center. Cancer 106:426–433CrossRefPubMed
29.
Gross CP, Filardo G, Mayne ST, Krumholz HM (2005) The impact of socioeconomic status and race on trial participation for older women with breast cancer. Cancer 103:483–491CrossRefPubMed
30.
Agrawal M, Grady C, Fairclough DL, Meropol NJ, Maynard K, Emanuel EJ (2006) Patients’ decision-making process regarding participation in phase I oncology research. J Clin Oncol 24:4479–4484CrossRefPubMed
31.
Avis NE, Smith KW, Link CL, Hortobagyi GN, Rivera E (2006) Factors associated with participation in breast cancer treatment clinical trials. J Clin Oncol 24:1860–1867CrossRefPubMed
32.
Catania C, De Pas T, Goldhirsch A, Radice D, Adamoli L, Medici M, Verri E, Marenghi C, de Braud F, Nole F (2008) Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choice. Oncology 74:177–187CrossRefPubMed
33.
Catt S, Langridge C, Fallowfield L, Talbot DC, Jenkins V (2011) Reasons given by patients for participating, or not, in phase 1 cancer trials. Eur J Cancer 47:1490–1497CrossRefPubMed
34.
Davison BJ, So A, Goldenberg SL, Berkowitz J, Gleave ME (2007) Measurement of factors influencing the participation of patients with prostate cancer in clinical trials: a Canadian perspective. BJU Int 101:982–987CrossRefPubMed
35.
Jenkins V, Fallowfield L (2000) Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. Br J Cancer 82:1783–1788CrossRefPubMedCentralPubMed
36.
Jones JM, Nyhof-Young J, Moric J, Friedman A, Wells W, Catton P (2006) Identifying motivations and barriers to patient participation in clinical trials. J Cancer Educ 21:237–242CrossRefPubMed
37.
Kemeny MM, Peterson BL, Kornblith AB, Muss HB, Wheeler J, Levine E, Bartlett N, Fleming G, Cohen HJ (2003) Barriers to clinical trial participation by older women with breast cancer. JCO 21:2268–2275CrossRef
38.
Schutta KM, Burnett CB (2000) Factors that influence a patient’s decision to participate in a phase I cancer clinical trial. Oncol Nurs Forum 27:1435–1438PubMed
39.
Truong TH, Weeks JC, Cook EF, Joffe S (2011) Altruism among participants in cancer clinical trials. Clin Trials 8:616–623CrossRefPubMed
40.
Wang LH, Tsai YF, Chen JS, Tsay PK (2011) Intention, needs, and expectations of cancer patients participating in clinical trials. Cancer Nurs 34:117–123CrossRefPubMed
41.
Wright JR, Whelan TJ, Schiff S, Dubois S, Crooks D, Haines PT, DeRosa D, Roberts RS, Gafni A, Pritchard K, Levine MN (2004) Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision. JCO 22:4312–4318CrossRef
42.
Mancini J, Genève J, Dalenc F, Genre D, Monnier A, Kerbrat P, Largillier R, Serin D, Rios M, Roché H, Jimenez M, Tarpin C, the Patients’ Committee for Clinical trials of the Ligue Nationale, Julian Reynier C (2007) Decision-making and breast cancer clinical trials: how experience challenges attitudes. Contemp Clin Trials 28:684–694CrossRefPubMed
43.
Meropol NJ, Buzaglo JS, Millard J, Damjanov N, Miller SM, Ridgway C, Ross EA, Sprandio JD, Watts P (2007) Barriers to clinical trial participation as perceived by oncologists and patients. J Natl Compr Canc Netw 5:655–664PubMed
44.
Sabesan S, Burgher B, Buettner P, Piliouras P, Otty Z, Varma S, Thaker D (2011) Attitudes, knowledge and barriers to participation in cancer clinical trials among rural and remote patients. Asia Pac J Clin Oncol 7:27–33CrossRefPubMed
45.
Solomon MJ, Pager CK, Young JM, Roberts R, Butow P (2003) Patient entry into randomized controlled trials of colorectal cancer treatment: factors influencing participation. Surgery 133:608–613CrossRefPubMed
46.
Weckstein DJ, Thomas CA, Emery IF, Shea BF, Fleury A, White ME, Chase E, Robinson C, Frazier S, Pilar C (2011) Assessment of perceived cost to the patient and other barriers to clinical trial participation. J Oncol Pract 7:330–333CrossRefPubMedCentralPubMed
47.
Li J, Yu C, Jiang Y (2010) Participation in cancer clinical trials as viewed by chinese patients and their families. Oncology 79:343–348CrossRefPubMed
48.
Roberson NL (1994) Clinical trial participation. Viewpoints from racial/ethnic groups. Cancer 74:2687–2691CrossRefPubMed
49.
Llewellyn-Thomas HA, McGreal MJ, Thiel EC, Fine S, Erlichman C (1991) Patients’ willingness to enter clinical trials: measuring the association with perceived benefits and preference for decision participation. Soc Sci and Med 32:35–42CrossRef
50.
Melisko ME, Hassin F, Metzroth L, Moore DH, Brown B, Patel K, Rugo HS, Tripathy D (2005) Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers. Clin Breast Cancer 6:45–54CrossRefPubMed
51.
Kim JW, Kim S, Chung Y, Kwon J, Lee H, Chung Y, Kim YJ, Oh D, Lee S, Kim D, Im S, Kim T, Heo DS, Bang Y (2008) Cancer patients’ awareness of clinical trials, perceptions on the benefit and willingness to participate: Korean perspectives. Br J Cancer 99:1593–1599CrossRefPubMedCentralPubMed
52.
Brown DR, Topcu M (2003) Willingness to participate in clinical treatment research among older African Americans and Whites. Gerontologist 43:62–72CrossRefPubMed
53.
Kornblith AB, Kemeny MM, Peterson BL, Wheeler J, Crawford J, Bartlett N, Fleming G, Graziano S, Muss H, Cohen JH, Cancer and Leukemia Group B (2002) Survey of oncologists’ perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 95:989–996CrossRefPubMed
54.
Nurgat ZA, Craig W, Campbell NC, Bissett JD, Cassidy J, Nicolson MC (2005) Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer 92:1001–1005CrossRefPubMedCentralPubMed
55.
LaVallie DL, Wolf FM, Jacobsen C, Buchwald D (2008) Barriers to cancer clinical trial participation among Native elders. Ethn Dis 18:210–217PubMed
56.
Ling J, Rees E, Hardy J (2000) What influences participation in clinical trials in palliative care in a cancer centre? Eur J Cancer 36:621–626CrossRefPubMed
57.
Flessig A, Jenkins V, Fallowfield L (2001) Results of an intervention study to improve communication about randomised clinical trials of cancer therapy. Eur J Cancer 37:322–331CrossRef
58.
Cox K, Avis M (1996) Psychosocial aspects of participation in early anticancer drug trials. Report of a pilot study. Cancer Nurs 19:177–186CrossRefPubMed
59.
Coyne CA, Demian-Popescu C, Brown P (2004) Rural cancer patients’ perspectives on clinical trials: a qualitative study. J Cancer Educ 19:165–169CrossRefPubMed
60.
Ellis PM, Butow PN (1998) Focus group interviews examining attitudes to randomised trials among breast cancer patients and the general community. Aust N Z J Public Health 22:528–531CrossRefPubMed
61.
Eng M, Taylor L, Verhoef M, Ernst S, Donnelly B (2005) Understanding participation in a trial comparing cryotherapy and radiation treatment. Can J Urol 12:2607–2613PubMed
62.
Grunfeld E, Zitzelberger L, Coristine M, Aspelund F (2002) Barriers and facilitators to enrollment in cancer clinical trials: qualitative study of the perspectives of clinical research associates. Cancer 95:1577–1583CrossRefPubMed
63.
Huizinga GA, Sleijfer DT, van de Wiel HB, van der Graaf WT (1999) Decision-making process in patients before entering phase III cancer clinical trials: a pilot study. Cancer Nurs 22:119–125CrossRefPubMed
64.
Kohara I, Inoue T (2010) Searching for a way to live to the end: decision-making process in patients considering participation in cancer phase I clinical trials. Oncol Nurs Forum 37:E124–32CrossRefPubMed
65.
Kvale EA, Woodby L, Williams BR (2010) The experience of older patients with cancer in phase 1 clinical trials: a qualitative case series. Am J Hosp Palliat Care 27:474–481CrossRefPubMed
66.
Madsen SM, Holm S, Riis P (2007) Attitudes towards clinical research among cancer trial participants and non-participants: an interview study using a grounded theory approach. J Med Ethics 33:234–240CrossRefPubMedCentralPubMed
67.
Mills N, Donovan JL, Wade J, Hamdy FC, Neal DE, Lane JA (2011) Exploring treatment preferences facilitated recruitment to randomized controlled trials. J Clin Epidemiol 64:1127–1136CrossRefPubMedCentralPubMed
68.
Schaefer KM, Ladd E, Gergits MA, Gyauch L (2001) Backing and forthing: the process of decision making by women considering participation in a breast cancer prevention trial. Oncol Nurs Forum 28:703–709PubMed
69.
Shah A, Efstathiou JA, Paly JJ, Halpern SD, Bruner DW, Christodouleas JP, Coen JJ, Deville C Jr, Vapiwala N, Shipley WU, Zietman AL, Hahn SM, Bekelman JE (2012) Prospective preference assessment of patients’ willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 83:e13–9CrossRefPubMed
70.
Shannon-Dorcy K, Drevdahl DJ (2011) “I had already made up my mind”: patients and caregivers’ perspectives on making the decision to participate in research at a US cancer referral center. Cancer Nurs 34:428–433CrossRefPubMed
71.
Stevens T, Ahmedzai SH (2004) Why do breast cancer patients decline entry into randomised trials and how do they feel about their decision later: a prospective, longitudinal, in-depth interview study. Patient Educ Couns 52:341–348CrossRefPubMed
72.
Ellis PM, Butow P (1998) Focus group interviews examining attitudes to randomized trials among breast cancer patients and the general community. Aust N Z J Public Health 22:528–531CrossRefPubMed
73.
Madsen SM, Mirza MR, Holm S, Hilsted KL, Kampmann K, Riis P (2002) Attitudes towards clinical research amongst participants and nonparticipants. J Intern Med 251:156CrossRefPubMed
74.
Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada. (2010) Tri-Council Policy Statement: ethical conduct for research involving humans
75.
Donchin A (2001) Understanding autonomy relationally: toward a reconfiguration of bioethical principles. J Med Philos 26:365–386CrossRefPubMed
76.
Ho A (2008) Relational autonomy or undue pressure? Family’s role in medical decision‐making. Scand J Caring Sci 22:128–135CrossRefPubMed
77.
Mackenzie C, Stoljar N (2000) Introduction: autonomy refigured. In: anonymous relational autonomy: feminist perspectives on autonomy, agency, and the social self. Oxford University Press, New York, pp 35–51
78.
Robinson CA (2011) Advance care planning: re-visioning our ethical approach. Can J Nurs Res 43:18–37PubMed
79.
80.
Candib LM (2002) Truth telling and advance planning at the end of life: problems with autonomy in a multicultural world. Fam Syst Health 20:213–228CrossRef
81.
Eliott J, Olver I (2008) Choosing between life and death: patient and family perceptions of the decision not to resuscitate the terminally ill cancer patient. Bioethics 22:179–189CrossRefPubMed
82.
Metadaten
Titel
Cancer patient decision making related to clinical trial participation: an integrative review with implications for patients’ relational autonomy
verfasst von
Jennifer A. H. Bell
Lynda G. Balneaves
Publikationsdatum
01.04.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 4/2015
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2581-9

Weitere Artikel der Ausgabe 4/2015

Supportive Care in Cancer 4/2015 Zur Ausgabe

Original Article

Dietary habits changes and quality of life in patients undergoing chemotherapy for epithelial ovarian cancer

Original Article

Cytokine gene variations associated with trait and state anxiety in oncology patients and their family caregivers

Original Article

Risk-reduction opportunities in breast cancer survivors: capitalizing on teachable moments

Review Article

Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents

Original Article

Comparison of the acceptability and benefits of two mindfulness-based interventions in women with breast or gynecologic cancer: a pilot study

Original Article

The oncology palliative care clinic at the Princess Margaret Cancer Centre: an early intervention model for patients with advanced cancer

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise